The US FDA has approved the application by Israel’s Teva for its SD-809 (deutetrabenazine) treatment for Huntington’s disease. SD-809 was part of Teva’s May acquisition of Auspex and has completed two Phase-III studies.

http://www.tevapharm.com/news/?itemid={B77B4464-664B-4DC5-8373-F7D040CE2327}